Therefore, anti-CD19-CAR T cells are part of the standard of care, amongst others, in refractory or relapsed diffuse large B cell lymphoma or acute lymphoblastic leukemia [1, 3]. Here, CD19 is linked to acute lymphoblastic leukemia.